Rimegepant
Indications
Rimegepant is used for:
Migraine Treatment
Adult Dose
Migraine Treatment
Indicated for acute treatment of migraine with or without aura
75 mg PO
Not to exceed 75 mg per 24-hr period
Safety of treatment >15 migraines/30 days has not been established
Hepatic impairment
Mild or moderate (Child-Pugh A or B): No dosage adjustment required
Severe: Avoid
Child Dose
Renal Dose
Renal impairment
Mild, moderate, or severe (CrCl ?15 mL/min): No dosage adjustment required
End-stage renal disease (CrCl <15 mL/min): Avoid; not studied
Administration
Use dry hands when opening blister pack
Peel back foil covering of 1 blister and gently remove the orally disintegrating tablet (ODT); do not push the ODT through the foil
As soon as the blister is opened, remove ODT and place on the tongue; alternatively, the ODT may be placed under the tongue
ODT disintegrates in saliva so that it can be swallowed without additional liquid
Take the ODT immediately after opening the blister pack; do not store ODT outside the blister pack for future use
Contra Indications
History of hypersensitivity to rimegepant; delayed serious hypersensitivity reported
Precautions
Hypersensitivity
Hypersensitivity reactions, including dyspnea and rash, reported
Hypersensitivity reactions can occur days after administration, and delayed serious hypersensitivity has occurred
If a hypersensitivity reaction occurs, discontinue rimegepant and initiate appropriate therapy
Pregnancy-Lactation
Pregnancy
Data are not available regarding the developmental risk associated with use in pregnant women
Clinical considerations
Data suggest that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy
Animal studies
Oral administration during organogenesis resulted in adverse effects on development in rats (decreased fetal body weight and increased incidence of fetal variations) at exposures greater than those used clinically and which were associated with maternal toxicity
Lactation
Data are not available on the presence in human milk, effects on breastfed infants, or effects on milk production
There are no animal data on the excretion of rimegepant in milk
Interactions
Side Effects
Side effects of Rimegepant :
1-10%
Nausea (2%)
<1%
Hypersensitivity, including dyspnea and severe rash
Mode of Action
Calcitonin gene-related peptide (CGRP) receptor antagonist; binds to CGRP receptor, which is thought to be causally involved in migraine pathophysiology